Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sime Darby Bioganics was a specialized biotechnology subsidiary of the Sime Darby Group, a major Malaysian conglomerate, focused on the extraction and commercialization of high-value phytonutrients from palm oil. The company was a pioneer in the production of tocotrienols, a potent form of Vitamin E, and mixed carotenoids, marketed under the brand names Gold Tri.E and Caromix. These products were developed using proprietary molecular distillation technology to serve the global pharmaceutical, nutraceutical, and functional food sectors. Sime Darby Bioganics actively supported clinical research into the benefits of tocotrienols for cardiovascular health, neuroprotection, and liver health. Following a corporate restructuring in 2017, the company's operations were integrated into Sime Darby Oils, specifically within its Nutrition division, where it continues to operate as a leader in palm-based bioactives.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sime Darby Bioganics.